MAP2K7 and breast cancer: We further tested whether Mek inhibition promotes covalent binding of ErbB2 to a protein ubiquitin and subsequent ErbB2 proteasomal degradation (a known mechanism of protein turnover [37]) in detached breast cancer cells.